Regal Assets Analytics

WDLangbein

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

Immunovant Pauses Dosing in Trials; Elevated Cholesterol Not Measured Yet in WAIHA Trial

By |2021-02-04T09:34:33-05:00February 3rd, 2021|Categories: SanaCurrents, SanaCurrents Updates|Tags: |

Immunovant (NASDAQ:IMVT) said Tuesday it had paused dosing patients in [...]

Turning Point Trial Records Positive Results; Matinas’ Drug Does Not Prove Superiority

By |2021-02-01T11:49:26-05:00February 1st, 2021|Categories: SanaCurrents, SanaCurrents Updates|Tags: , |

Turning Point Therapeutics, Inc (NASDAQ:TPTX) said over the weekend that [...]

Turning Point to present data from lung cancer trial; SanaCurrents closing out Aurina

By |2021-02-01T11:02:57-05:00January 31st, 2021|Categories: SanaCurrents, SanaCurrents Updates|Tags: , |

Data from Turning Point Therapeutics’ (NASDAQ:TPTX) phase II trial of [...]

AnaptysBio (ANAB) Probability Sentiment

By |2021-01-31T17:44:12-05:00January 29th, 2021|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: |

Anaptysbio, Inc. (NASDAQ:ANAB) Probability Sentiment [...]

Go to Top